Human Papillomavirus Prevalence Among American Indian Women of the Great Plains

Lee, Naomi; Cherne, Stephen; Noonan, Carolyn; Nelson, Lonnie A.; Gonzales, Angela A.; Umans, Jason G.; Buchwald, Dedra; Outcomes, Collaborative to Improve Native Cancer

doi:10.1093/infdis/jiy600

Cited by 12 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, the Pap screenings were augmented with the HPV vaccine and hrHPV type-specific testing. However, despite the decline, U.S. cancer registries with linkage to Indian Health Service (IHS) records showed a 25% higher rate of cervical cancer incidence and mortality in Native women when compared with Hispanic non-white women, with a nearly two-fold variation across IHS regions [ 6 , 7 , 8 ]. Several studies also showed that, for most U.S. regions, cervical cancer mortality rates among Native women are consistently higher than those for all other races [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, among two separate studies in Native American women, HPV-16 was the least prevalent. Alarmingly, HPV-51 was the most prevalent among Native women and is not covered by the current HPV vaccines [ 7 , 13 ]. Since the introduction of the HPV vaccines, hrHPV prevalence decreased among women eligible for vaccination, specifically for HPV-16 and -18 [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Despite a global and nationwide decrease, Native Americans continue to experience high rates of cancer morbidity and mortality. Vaccination is one approach to decrease cancer incidence such as the case of cervical cancer. However, the availability of vaccines does not guarantee uptake, as evident in the Coronavirus 2019 pandemic. Therefore, as we consider current and future cancer vaccines, there are certain considerations to be mindful of to increase uptake among Native Americans such as the incidence of disease, social determinants of health, vaccine hesitancy, and historical exclusion in clinical trials. This paper primarily focuses on human papillomavirus (HPV) and potential vaccines for Native Americans. However, we also aim to inform researchers on factors that influence Native American choices surrounding vaccination and interventions including cancer therapies. We begin by providing an overview of the historical distrust and trauma Native Americans experience, both past and present. In addition, we offer guidance and considerations when engaging with sovereign Tribal Nations in vaccine development and clinical trials in order to increase trust and encourage vaccine uptake.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the next most frequent causes of death in AI/ANs are quite different from the general population, with intentional or unintentional injury, diabetes, and chronic liver disease among the next most common ( Espey et al, 2014 ). Another example highlighting the importance of AI/AN participation in research was a study of high-risk Human Papillomavirus Virus (hrHPV) in AI women where Lee et al found that the single most prevalent hrHPV genotype (HPV-51) was quite different from the prevalence in the general population, and this genotype was not covered by the extant HPV vaccines ( Lee et al, 2019 ). This information, which directly impacts health care and cancer prevention, was uncovered only because of participation by a large number of AI women and their willingness to donate biospecimens.…”

Section: Introductionmentioning

confidence: 99%

Increasing health equity through biospecimen research: Identification of factors that influence willingness of Native Americans to donate biospecimens

Sinclair

Muller

Noonan

et al. 2021

Preventive Medicine Reports

View full text Add to dashboard Cite

“…Contrarily, high-risk HPV (HR-HPV) type cause cervical, anal, and other genital cancers, which could be detected in 99% of cervical cancers-the second most common cancer in women worldwide. HPV16 and -18 have been found to be the most pathogenic of the HR-HPV types, causing about 70% of cervical cancers worldwide [7][8][9][10]. Of note, most HPV infections are completely asymptomatic, resulting in a delay in diagnosis and follow-up treatment with disastrous consequences [11].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and genotype distribution of HPV infection among 214,715 women from Southern China, 2012-2018: baseline measures prior to mass HPV vaccination

Luo

Qiao-tu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The epidemiology on the human papillomavirus (HPV) among females in Southern China is not well-established. Baseline data on the prevalence of HPV infection in China prior to mass prophylactic HPV vaccination would be useful. Thus, this study aimed to determine the type-specific HPV prevalence and distribution among females from Southern China prior to mass HPV vaccination. Methods: A retrospective cross-sectional study employing 214,715 women attending ChenZhou NO.1 People’s Hospital for cervical screening during 2012-2018 was conducted prior to widespread HPV vaccination. HPV genotype was detected using nucleic acid molecular diversion hybridization tests. The overall prevalence, age-specific prevalence, type distribution, and annual trend were analyzed. Results: The overall HPV prevalence was 18.71% (95% confidence interval [CI], 18.55%-18.88%) among Southern China females. During 2012–2018, the prevalence of HPV infection showed a downward tendency, from 21.63% (95% CI, 21.07%-22.20%) in 2012 to 18.75% (95% CI, 18.35%-19.16%) in 2018. Age-specific HPV distribution displayed a peak at young women aged less than 21 years (33.11%, 95% CI, 31.13%-35.15%), 20.07% (95% CI, 19.70%-20.44%) among women aged 21-30 years, 17.29% (95% CI, 17.01%-17.57%) among women aged 31-40 years, 17.23% (95% CI, 16.95%-17.51%) among women aged 41-50 years, 21.65% (95% CI, 21.11%-22.20%) among women aged 51-60 years, and 25.95% (95% CI, 24.86%-27.07%) among women aged over 60 years. Of the 21 subtypes identified, the most three prevalent high-risk HPV (HR-HPV) genotypes were HPV52 (5.12%; 95% CI, 21.11%-22.20%), -16 (2.96%; 95% CI, 2.89%-3.03%), and -58 (2.51%; 95% CI, 2.44%-2.58%); the predominant low-risk HPV (LR-HPV) genotypes were HPV81 (1.86%; 95%CI, 1.80%-1.92%) and -6 (0.69%; 95% CI, 0.66%-0.73%) respectively. Incidence of HR-HPV only, LR-HPV only and mixed LR- and HR-HPV were 15.17%, 2.07% and 1.47% respectively. Besides, single HPV infection accounted for 77.30% of all positive cases in this study.Conclusions: This study highlights 1) a high prevalence of HPV infection among females with a decreasing tendency towards 2012-2018, especially for young women under the age of 21 prior to mass HPV vaccination; 2) HPV52, -16 and -58 were the predominant HPV genotypes, suggesting potential use of HPV vaccine covering these HPV genotypes in Southern China.

show abstract

Human Papillomavirus Prevalence Among American Indian Women of the Great Plains

Cited by 12 publications

References 39 publications

Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review

Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review

Increasing health equity through biospecimen research: Identification of factors that influence willingness of Native Americans to donate biospecimens

Prevalence and genotype distribution of HPV infection among 214,715 women from Southern China, 2012-2018: baseline measures prior to mass HPV vaccination

Contact Info

Product

Resources

About